Fisher Asset Management LLC purchased a new stake in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) in the fourth quarter, Holdings Channel reports. The firm purchased 5,282 shares of the company’s stock, valued at approximately $241,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cubist Systematic Strategies LLC boosted its holdings in shares of Pacira Pharmaceuticals by 121.5% in the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock valued at $152,000 after purchasing an additional 1,752 shares during the period. QS Investors LLC purchased a new stake in shares of Pacira Pharmaceuticals in the second quarter valued at approximately $157,000. Ameritas Investment Partners Inc. boosted its holdings in shares of Pacira Pharmaceuticals by 9.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock valued at $165,000 after purchasing an additional 302 shares during the period. Spectrum Management Group Inc. purchased a new stake in shares of Pacira Pharmaceuticals in the third quarter valued at approximately $166,000. Finally, Bouchey Financial Group Ltd purchased a new stake in shares of Pacira Pharmaceuticals in the fourth quarter valued at approximately $205,000.

In other Pacira Pharmaceuticals news, Director Mark A. Kronenfeld acquired 1,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was purchased at an average price of $41.60 per share, for a total transaction of $41,600.00. Following the acquisition, the director now owns 6,795 shares in the company, valued at approximately $282,672. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP James B. Jones sold 850 shares of the stock in a transaction on Monday, November 20th. The shares were sold at an average price of $41.11, for a total value of $34,943.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 98,960 shares of company stock valued at $3,868,341. Company insiders own 6.60% of the company’s stock.

Shares of Pacira Pharmaceuticals Inc (NASDAQ:PCRX) opened at $38.50 on Friday. Pacira Pharmaceuticals Inc has a twelve month low of $29.81 and a twelve month high of $58.95. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $1,540.00, a price-to-earnings ratio of -29.39 and a beta of 1.88.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The firm had revenue of $67.30 million during the quarter, compared to analyst estimates of $68.99 million. During the same quarter in the prior year, the business posted $0.20 EPS. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. sell-side analysts expect that Pacira Pharmaceuticals Inc will post -0.86 earnings per share for the current year.

A number of analysts recently issued reports on the company. BidaskClub lowered Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, January 26th. Canaccord Genuity lowered their target price on Pacira Pharmaceuticals from $46.00 to $42.00 and set a “hold” rating for the company in a report on Tuesday, January 30th. Seaport Global Securities assumed coverage on Pacira Pharmaceuticals in a report on Friday, January 19th. They set a “buy” rating and a $50.00 target price for the company. HC Wainwright restated a “buy” rating and set a $52.00 target price on shares of Pacira Pharmaceuticals in a report on Thursday, November 9th. Finally, Mizuho lowered Pacira Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $53.00 to $44.00 in a report on Wednesday, November 29th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $48.82.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with's FREE daily email newsletter.